Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from EUDA Health Holdings ( (EUDA) ).
On January 13, 2026, EUDA Health Holdings Limited further amended a previously issued warrant held by Streeterville Capital, LLC, originally issued on December 4, 2025 under a November 26, 2025 securities purchase agreement. The second amendment cut the warrant’s exercise price in half, from $4.00 to $2.00 per ordinary share, and lowered the minimum Nasdaq closing price required to trigger a forced cash exercise to $3.00, while also tying any forced exercise to minimum trading price and volume conditions and capping the number of shares that can be forced to 10% of measured trading volume. EUDA plans to file a new prospectus supplement under its effective Form F-3 registration statement to reflect the revised warrant terms, a move that could make it more attractive for the investor to exercise the warrant and thus potentially accelerate equity financing for the company, albeit at a lower per-share price than previously agreed.
The most recent analyst rating on (EUDA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on EUDA Health Holdings stock, see the EUDA Stock Forecast page.
More about EUDA Health Holdings
EUDA Health Holdings Limited is a British Virgin Islands-incorporated company operating in the healthcare sector, with principal executive offices in Singapore. The company is listed on Nasdaq and utilizes capital markets instruments, including warrants and registered offerings under a Form F-3 shelf registration, to finance its operations and growth initiatives in its healthcare-focused business.
Average Trading Volume: 349,341
Technical Sentiment Signal: Sell
Current Market Cap: $87.34M
For detailed information about EUDA stock, go to TipRanks’ Stock Analysis page.